Diclofenac in Europe an update

Similar documents
Opinion of the Committee for Medicinal Products for Veterinary Use pursuant to Article 30(3) of Regulation (EC) No 726/2004

Ban veterinary diclofenac

CVMP activities regarding antimicrobials Ongoing and recent activities

Scientific Discussion post-authorisation update for Rheumocam extension X/007

Fringilla coelebs all others

This document is available on the English-language website of the Banque de France

SUMMARY OF PRODUCT CHARACTERISTICS

No July 2000 REGULATION. respecting veterinarians authorisations to prescribe drugs SECTION II

Request for advice on the impact on public health and animal health of the use of antibiotics in animals

CVMP assessment report under Article 30(3) of Regulation (EC) No 726/2004

Council of the European Union Brussels, 13 June 2016 (OR. en)

Procedures for the Taking of Prevention and Eradication Measures of Brucellosis in Bovine Animals

Carduelis chloris. Report under the Article 12 of the Birds Directive Period Annex I International action plan. No No

HMA-V Action plan on antimicrobial issues Version for publication (27 January 2011)

COMMISSION OF THE EUROPEAN COMMUNITIES. Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

European Medicines Agency role and experience on antimicrobial resistance

Prof. Otto Cars. We are overconsuming a global resource. It is a collective responsibility by governments, supranational organisatons

COMMISSION IMPLEMENTING DECISION

COMMISSION DELEGATED REGULATION (EU)

Veterinary antimicrobials: state of play and future developments 2013 European Medicines Agency/IFAH- Europe Info Day 7-8 March 2013

EU Market Situation for Eggs. Civil Dialogue Group. 17 February 2017

Asio otus. Report under the Article 12 of the Birds Directive Period Annex I International action plan. No No

COMMISSION DELEGATED REGULATION (EU) /... of XXX

Draft ESVAC Vision and Strategy

PRESS RELEASE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

EU Market Situation for Poultry. Committee for the Common Organisation of the Agricultural Markets 23 July 2015

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE

Company: Richter Pharma AG MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

CONSERVATION OF IBERIAN VULTURES. Overarching Workshop to Develop a Multi-species Action Plan to Conserve African- Eurasian Vultures

RUMA: Advocating Prudent Use of Antimicrobial Compounds

Legislation on Veterinary Medicinal Products (VMPs) and legal status of relevant VMPs for anesthesia of finfish

Stop overuse of antibiotics in humans rational use

Assessment of compliance of current legislation: Veterinary Products Act

MRSA found in British pig meat

Regulatory approaches to ensure the safety of pet food

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

SUMMARY OF PRODUCT CHARACTERISTICS

Standard operating procedure

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Special Eurobarometer 445. Summary

Special Eurobarometer 478. Summary. Antimicrobial Resistance

Issue Overview: Antibiotic resistance

LIFE.2.B EUROPEAN UNION. Brussels, 14 November 2018 (OR. en) 2014/0255 (COD) PE-CONS 43/18 AGRILEG 102 VETER 52 CODEC 1149

This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents

EU Market Situation for Poultry. Committee for the Common Organisation of the Agricultural Markets 23 October 2014

This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents

[09/2018] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

EU Market Situation for Eggs. Committee for the Common Organisation of the Agricultural Markets 21 May 2015

Dr Elisabeth Erlacher Vindel Head of Science and New Technologies Departement OIE AMR strategy and activities related to animal health

Reflection paper on promotion of pharmacovigilance reporting

EMA advice on the impact of the use of antibiotics on public and animal health: Potential impact on the authorisation of antimicrobials

Evaluation of EU strategy to combat AMR

Quality of Veterinary Medicinal Products. How to ensure the quality of Veterinary Medicinal Products

Stratégie et action européennes

EU strategy to fight against Antimicrobial Resistance

Antimicrobial Resistance

Metacam is an anti-inflammatory medicine used in cattle, pigs, horses, dogs, cats and guinea pigs.

European Antibiotic Awareness Day

Combat Antimicrobial Resistance

Further memorandum submitted by the Department for Environment, Food and Rural Affairs

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

European trends in animal welfare policies and research and their potential implications for US Agriculture

Results of the questionnaire on Veterinary Medicinal Products in the Middle East Damascus, Syria, 2-4 December 2009

HEALTH & CONSUMERS DIRECTORATE-GENERAL

SUMMARY OF PRODUCT CHARACTERISTICS. Euthasol vet. 400 mg/ml, solution for injection (AT, BE, DK, EE, EL, FI, IE, IS, LT, LU, LV, NO, PL, RO SE, UK)

European Public MRL assessment report (EPMAR)

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses

My 4-H Animal Project

RESTRAINING SYSTEMS FOR BOVINE ANIMALS SLAUGHTERED WITHOUT STUNNING WELFARE AND SOCIO-ECONOMIC IMPLICATIONS

Sales survey of veterinary medicinal products containing antimicrobials in France in Annual report

EPAR type II variation for Metacam

COMMISSION OF THE EUROPEAN COMMUNITIES REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL

COMMISSION IMPLEMENTING REGULATION (EU)

(Text with EEA relevance)

Official controls on products of animal origin: Art. 18 of Regulation (EU) 2017/625

World Organisation for Animal Health

OVER 30 MONTH CATTLE SLAUGHTER RULE (OTM Rule)

Trichinella: Contingency plan upon detection of Trichinella in animals in Denmark

PRESS RELEASE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

ESTONIAN STATE AGENCY OF MEDICINES LATVIAN FOOD AND VETERINARY SERVICE LITHUANIAN NATIONAL FOOD AND VETERINARY RISK ASSESSMENT INSTITUTE

Antimicrobial Resistance

OIE Strategy on Antimicrobial Resistance and the Prudent Use of Antimicrobials in Animals Part I

Working for organic farming in Europe

The benefits of I&R for cats and dogs EU Parliament - Strasbourg 8 September Dr. Paolo Dalla Villa

Fipronil in eggs. Ladislav MIKO - Deputy Director General

Dr. Gérard Moulin AFSSA/ANMV OIE Collaborating Centre on Veterinary medicinal products BP FOUGERES CEDEX, FRANCE

UBA and Tukes concerned about the environmental impacts of veterinary medicines

Quality of Veterinary Medicinal Products. How to ensure the quality of Veterinary Medicinal Products

ARCI Controlled Therapeutic Medication Schedule for Horses - Version 4.1 Revised January, 2019

Work of Regional Representations supporting the implementation of the OIE standards on animal welfare

Monthly report on application procedures, guidelines and related documents for veterinary medicines

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12

SUMMARY OF PRODUCT CHARACTERISTICS

Global animal production perspectives and correlated use of antimicrobial agents

Update on European Agencies activities in the field of AMR

Irish Medicines Board

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Transcription:

Diclofenac in Europe an update Diclofenac: non-steroidal anti-inflammatory substance Vet diclofenac caused 95-99% decline in Indian Gyps vultures in 20 years Vet diclofenac in Europe Safe alternative exists Legal availability of diclofenac in Europe causes a precedent and a conduit for a global boom in veterinary diclofenac worldwide

Diclofenac kills vultures Kidney failure Death within two days LD50 (dose at which half of the vultures die): 0.098-0.225 mg p.o. Toxicity up to 1 week after diclofenac treatment withdrawal periods for diclofenac: 12 days for pigs & 15 days for cattle.

Diclofenac in Europe Manufactured by Italian company (FATRO) Used in cattle, pigs and horses, subject to veterinary prescription, and application by veterinaries (intravenous) or under vet supervision (intramuscular) Used to treat mastitis-metritis on lactating females, respiratory diseases (bronchopneumonia) and pathologies of the muscleskeleton (tendinitis, myositis, arthritis First authorised in 1993 (Italy) Since 2009 in a number of countries (Estonia, Czech Republic, Latvia) 2013 in Spain

Diclofenac in Europe Between 9,460 and 27,700 animals were treated with diclofenac in Spain during the first year of marketing of this drug alone 10% of diclofenac used in animals in extensive pastures Spanish gov. estimated: 15 39 Eurasian griffon vultures will die /year Green & Margalida (2014): 683-4792/year

Diclofenac in Europe time line 2009 - Approved in Italy (Reuflogin) 2013 - Approved in Spain (Diclovet & Dolofenac) Dec 2013 VCF informed Jan 2014 VCF and other conservation organisations write and meet EU Commission and ask for banning of diclofenac Mar 2014 - VCF & others contact FATRO and asks for voluntary withdrawal of the market refused 2014 - VCF & others campaign. Press work. Petition (50,000 signatures). IUCN, CMS, WCS, EAZA, SCB, OIE all support campaign

VULTURE CONSERVATION FOUNDATION

VULTURE CONSERVATION FOUNDATION

Diclofenac in Europe time line Aug 2014 - EU Commission asks the European Medicine Agency (EMA) for scientific opinion Oct-Nov 2014 public consultation and hearing. VCF contributes Dec 2014 - EMA decision

EMA Decision Confirmed risk for vultures and other necrophagous birds in the European Union Risk identified at two exposure scenarios - feeding stations from non-slaughterhouse material and fallen stock

EMA Decision Considers that further regulatory action is needed (e.g. implementation of additional risk management measures) These are wide ranging, from banning the drug to labelling EMA could not evaluate the effectiveness of all of the proposed measures as several of them cannot be quantified at present or do not fall within its remit. Therefore, it did not make a recommendation on which of them would be most appropriate.

EMA Decision Annex I Summary of considered risk management measures Information to veterinarians Warnings in the product literature Change in the administration pattern of the VMP Changes in the food chain information Increase controls in farms intentionally leaving dead animals in the field Accompanying of document for by-products Sampling scheme Withdraw diclofenac products from the EU market In conclusion, the EMA was of the opinion that additional risk management measures are needed and efforts should focus on determining the most suitable and effective ones to ensure that contaminated carcasses do not end up in the food chain of vultures and other necrophagous birds.

Diclofenac in Europe time line Dec 2014 - EMA decision Feb 2015 EU Commission decides, after consulting with member states (MS), NOT ban the drug, and asked MS to develop mitigation plans, to submit by April Jun 2015 National action plans submitted to the EU

National Mitigation Action Plans 1. Information to veterinarians - BG, CZ, LI, PL, ES, SE, IT 2. Warnings in the product literature - BG, CZ, EE, IT, ES, SE, IT 3. Changes in the administration pattern of the VMP - BG, CZ, EE 4. Changes in the food chain information - PT, IT 5. Increase controls in farms intentionally leaving dead animals in the field - PT, IT 6. Accompanying of document for by-products - PT 7. Sampling scheme - HR, CY, ES 8. Withdraw diclofenac products from the EU market - AT, SE

National Mitigation Action Plans - Italy Italy takes almost no measures. They have amended the labelling indicating that animals treated cannot be fed to wild fauna and not put on feeding stations, and that animals can only be sent out grazing after the withdrawal period. They also previously send out note to feeding stations and veterinarians

National Mitigation Action Plans - Spain Spain takes even less measures. They have amended the labelling a general sentence indicating that Diclofenac should not be administered to animals that will be eaten by wild fauna. They send out a note to veterinarians. They are planning to set up a scheme to test sick and dead vultures, but at first will rely on the wildlife rescue centres to provide them with information. Spain explicitly decides not to change the prescription method, as they claim it is not practically possible. They also will not change the Food Chain information and the documentation of byproducts.

Last year s meeting Implement public campaign to detect head dropping birds not done - capacity Explore diclofenac in water in farms in Spain line cost!!! Continue work in press, work with vets and advocacy - ongoing

Diclofenac in Europe future options Lobbying/Advocacy Member states to improve action plans Continue to battle for ban Press work Sampling in the field In Andalucia, only 15% of all tissue vulture corpses taken to centers were tested against diclofenac presence (5 griffons in 2014-2015)

Beyond Diclofenac Vet drugs (NSAIDs, euthanasia agents, antibiotics) - probably a bigger threat than we think or know Fluxinin, anti-parasitics EU risk assessment guidelines + testing toxicity of existing and new drugs on vultures